Suscribirse

Population-based screening for hemochromatosis using phenotypic and DNA testing among employees of health maintenance organizations in Springfield, Missouri - 08/09/11

Doi : 10.1016/S0002-9343(99)00163-1 
Sharon M McDonnell, MD, MPH a, , Alexander Hover, MD b, Donna Gloe, RN b : EdD, Chin-Yih Ou, PhD c, Mary E Cogswell, DrPH a, Laurence Grummer-Strawn, PhD a
a Maternal and Child Nutrition Branch (SMM, MEC, LG-S), Division of Nutrition and Physical Activity, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, USA 
b St. John’s Health Regional Health System (AH, DG), Department of Quality Resources, Springfield, Missouri, USA 
c Molecular Biology Branch (C-YO), Division of Environmental Health Laboratory Sciences, National Center for Environmental Health, Centers for Disease Control and Prevention, Atlanta, Georgia, USA 

*Requests for reprints should be addressed to Sharon M. McDonnell, MD, MPH, CDC, Mail Stop C-08, 1600 Clifton Road, Atlanta, Georgia 30333

Abstract

BACKGROUND: Hemochromatosis reportedly affects 3 to 8 persons per 1,000 and is associated with an elevated risk of morbidity and mortality. We sought to ascertain its prevalence in a community and to assess the association between phenotype and genotype.

METHODS: All health maintenance organization employees were invited to participate in hemochromatosis screening using a repeated elevation of the transferrin saturation test as the case definition (≥50% in women and ≥60% in men with no other cause). Iron overload from hemochromatosis was defined as serum ferritin concentration ≥95th percentile and mobilizable iron ≥99th percentile for age and sex, or hepatic iron index ≥1.9. The HFE gene was analyzed for mutations.

RESULTS: Participation among employees was 28% (1,653 of 6,000); 83% were women. The prevalence of hemochromatosis was 8 per 1,000 (13 of 1,653), and the prevalence of iron overload from hemochromatosis was 4 per 1,000 (5 of 1,653). Compared with those who had no HFE mutation, the relative risk (RR) for hemochromatosis was greatest for C282Y homozygotes (RR = 147), compound heterozygotes (RR = 19), and H63D homozygotes (RR = 9). Overall, 38% of participants had at least one HFE mutation. Screening based on an initial elevated transferrin saturation test had the best sensitivity, whereas DNA testing offered the best specificity and predictive value positive for iron overload disease.

CONCLUSIONS: In this population, we found a greater than expected prevalence of hemochromatosis and demonstrated a clear association with the HFE genotype. Promotion of screening is complicated by controversies in case definition and the large number of persons who will be detected before they have clinically significant iron loading, in whom the risk of clinical disease is unknown. Larger screening studies in more diverse populations are necessary to characterize the burden of disease and to follow those at risk (based on HFE or iron status measures) to establish the natural history of hemochromatosis.

El texto completo de este artículo está disponible en PDF.

Esquema


 Supported by the Centers for Disease Control and Prevention Grant number 1700.


© 1999  Excerpta Medica Inc. Reservados todos los derechos.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 107 - N° 1

P. 30-37 - juillet 1999 Regresar al número
Artículo precedente Artículo precedente
  • Upper and lower gastrointestinal evaluation of elderly inpatients who are iron deficient
  • Etienne Joosten, Bart Ghesquiere, Hilde Linthoudt, Francis Krekelberghs, Eddy Dejaeger, Steven Boonen, Johan Flamaing, Walter Pelemans, Martin Hiele, Anne-Marie Gevers
| Artículo siguiente Artículo siguiente
  • Does a year make a difference? changes in physician satisfaction and perception in an increasingly capitated environment
  • Eric S Nadler, Suzanne Sims, Patrick H Tyrance, David G Fairchild, Troyen A Brennan, David W Bates

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

¿Ya suscrito a @@106933@@ revista ?

@@150455@@ Voir plus

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2026 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.